|
Remdesivir For the Treatment of High-Risk Non-Hospitalized Individuals with COVID-19: A Randomized, Double, Blind, Placebo-Controlled Trial PINETREE Study -RDV for 3 day 87% reduction in hospitalization, there were no deaths in either arm
|
|
|
ID Week 2021
![1203211](../images/120321/120321-1/1203211.gif)
![1203212](../images/120321/120321-1/1203212.gif)
![1203213](../images/120321/120321-1/1203213.gif)
![1203214](../images/120321/120321-1/1203214.gif)
![1203215](../images/120321/120321-1/1203215.gif)
![1203216](../images/120321/120321-1/1203216.gif)
![1203217](../images/120321/120321-1/1203217.gif)
![1203218](../images/120321/120321-1/1203218.gif)
|
|
|
|
|
|
|